John Saia - Guardant Health Chief Secretary

GH Stock  USD 31.67  0.54  1.73%   

Executive

John Saia is Chief Secretary of Guardant Health
Age 51
Address 3100 Hanover Street, Palo Alto, CA, United States, 94304
Phone855 698 8887
Webhttps://guardanthealth.com

John Saia Latest Insider Activity

Tracking and analyzing the buying and selling activities of John Saia against Guardant Health stock is an integral part of due diligence when investing in Guardant Health. John Saia insider activity provides valuable insight into whether Guardant Health is net buyers or sellers over its current business cycle. Note, Guardant Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Guardant Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Guardant Health Management Efficiency

The company has Return on Asset (ROA) of (0.1608) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1608. This is way below average. Likewise, it shows a return on total equity (ROE) of (6.0928) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.38. As of now, Guardant Health's Intangible Assets are increasing as compared to previous years. The Guardant Health's current Fixed Asset Turnover is estimated to increase to 2.51, while Total Assets are projected to decrease to under 1.4 B.
Guardant Health reports 1.35 B of total liabilities with total debt to equity ratio (D/E) of 4.32, which implies that the company may not be able to produce enough cash to satisfy its debt commitments. Guardant Health has a current ratio of 6.06, indicating that it is in good position to pay out its debt commitments in time. Note however, debt could still be an excellent tool for Guardant to invest in growth at high rates of return.

Similar Executives

Showing other executives

EXECUTIVE Age

Ross PortaroVenus Concept
60
Christine McCauleyEdwards Lifesciences Corp
59
Yoni IgerVenus Concept
64
Andrew DahlEdwards Lifesciences Corp
47
Joel DavisDoximity
N/A
Arnold PinkstonEdwards Lifesciences Corp
65
Craig OverpeckDoximity
N/A
Bruno MirandaDoximity
N/A
Mark MSOutset Medical
67
Matthew RudermanDefinitive Healthcare Corp
N/A
Daniel LippisEdwards Lifesciences Corp
48
Marc NashOutset Medical
35
Arnold JDEdwards Lifesciences Corp
65
Jacques MourrainVeeva Systems Class
N/A
Anat KotlerVenus Concept
40
Matthew RobinsonVeeva Systems Class
50
Richard CPADefinitive Healthcare Corp
55
Gary SorsherEdwards Lifesciences Corp
59
Michael MandarelloVenus Concept
38
Michele OConnorVeeva Systems Class
47
Craig HazenfieldDefinitive Healthcare Corp
N/A
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 1373 people. Guardant Health (GH) is traded on NASDAQ Exchange in USA. It is located in 3100 Hanover Street, Palo Alto, CA, United States, 94304 and employs 1,768 people. Guardant Health is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Guardant Health Leadership Team

Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
AmirAli Talasaz, President COO, Director
Jennifer Higgins, Senior Affairs
Stephen Murphy, Senior Marketing
John Saia, Chief Secretary
Christopher Freeman, Chief Officer
John JD, Chief Secretary
Zarak Khurshid, Vice Relations
Helmy Eltoukhy, CoCEO CoFounder
Terilyn Monroe, Chief Officer
Craig MD, Chief Officer
Andy Ament, VP Operations
Kumud Kalia, Chief Officer
Michael Bell, Chief Officer
Darya Chudova, VP Technology
Darl Moreland, Senior Quality

Guardant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.28)
Revenue Per Share
5.7
Quarterly Revenue Growth
0.339
Return On Assets
(0.16)
Return On Equity
(6.09)
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.